Erectile Dysfunction Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Erectile
Dysfunction – Pipeline Review, H1 2019” drug pipelines has been
added to ResearchAndMarkets.com’s offering.

Erectile Dysfunction – Pipeline Review, H1 2019, provides comprehensive
information on the therapeutics under development for Erectile
Dysfunction (Male Health), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.

The Erectile Dysfunction (Male Health) pipeline guide also reviews of
key players involved in therapeutic development for Erectile Dysfunction
and features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities /Institutes,
the molecules developed by Companies in Pre-Registration, Filing
rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery
and Unknown stages are 1, 3, 2, 5, 7, 10, 1 and 2 respectively.
Similarly, the Universities portfolio in Phase II and Preclinical stages
comprises 1 and 2 molecules, respectively.

Erectile Dysfunction (Male Health) pipeline guide helps in identifying
and tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Erectile Dysfunction (Male Health).
• The pipeline guide reviews pipeline therapeutics for Erectile
  Dysfunction (Male Health) by companies and universities/research
  institutes based on information derived from company and
  industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Erectile
  Dysfunction (Male Health) therapeutics and enlists all their major and
  minor projects.
• The pipeline guide evaluates Erectile Dysfunction (Male Health)
  therapeutics based on mechanism of action (MoA), drug target, route of
  administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Erectile Dysfunction (Male Health)

Companies Mentioned

• Adamis Pharmaceuticals Corp
• Aquestive Therapeutics Inc
• Astellas Pharma Inc
• Biozeus Pharmaceutical SA
• Can-Fite BioPharma Ltd
• Cure Pharmaceutical Inc
• Fabre-Kramer Pharmaceuticals Inc
• Futura Medical Plc
• Humanetics Corp
• Karessa Pharma Holding AB
• Mezzion Pharma Co Ltd
• Mitsubishi Tanabe Pharma Corp
• NAL Pharmaceuticals Ltd
• Pharmicell Co Ltd
• SK Chemicals Co Ltd
• Suda Pharmaceuticals Ltd
• XuanZhu Pharma Co Ltd
• Yangtze River Pharmaceutical Group

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/73b742

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Sexual
and Reproductive Health Drugs